Semaglutide

FDA-approved

Calculate Dose

For research use only.

Key Facts

CAS: 910463-68-2
Molecular Weight (MW): 4113.58 g/mol
Half-life: ~7 days
Unit: mcg
Administration Route: Subcutaneous (inj.) or oral (tablet)
Frequency: Once weekly
Last updated: 12/14/2025
Targets: GLP-1 receptorPancreatic beta cellsCentral nervous systemGastrointestinal tract

Overview

—

Protocol

Dosage Range: 0.25-2.4 mg weekly (weight loss) or 0.5-1.0 mg weekly (diabetes)
Frequency: Once weekly
Cycle: Long-term use as prescribed
Administration Route: Subcutaneous (inj.) or oral (tablet)
Reconstitution Guide: Prefilled pen - no reconstitution needed

Science

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects.

Targets

GLP-1 receptorPancreatic beta cellsCentral nervous systemGastrointestinal tract

Studies

STEP trials: Semaglutide for weight management— Journal/year not available
SUSTAIN trials: Semaglutide for type 2 diabetes— Journal/year not available

Benefits

Significant weight loss (up to 15% body weight)Improved glycemic control in type 2 diabetesReduced cardiovascular riskLower blood pressureImproved lipid profile